{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:56:50Z","timestamp":1777859810377,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:p>Background and Objectives: The risk of serotonin syndrome (SS), especially when linezolid is used concomitantly with methadone, buprenorphine, and\/or dextroamphetamine, remains widely unstudied and may limit the options for antimicrobial therapy in these patient populations. Methods: We reviewed all adult encounters on linezolid with concomitant methadone, buprenorphine, and\/or dextroamphetamine from April 2016 to June 2022. The primary outcomes included characterizing prescribing preferences and prevalence of confirmed and possible serotonin syndrome using ICD-10 diagnosis codes, cyproheptadine administration, and electronic medical record chart review using the Hunter Serotonin Toxicity Criteria. Results: Overall, 194 encounters were evaluated. 16.5%, 17.8%, and 7.1% were on high dose methadone, buprenorphine, and dextroamphetamine, respectively. Mean duration of overlap with linezolid was 4.6, 3.3, and 7 days respectively. One confirmed and two possible cases of serotonin syndrome were identified. Conclusion: Linezolid may be considered in patients who are concomitantly on methadone, buprenorphine, and\/or dextroamphetamine. In our analysis of 194 encounters, one definitive case and two possible cases of SS were identified. Additional real-world studies are necessary to identify if exposure and\/or duration may be correlated with an increased risk of serotonin syndrome.<\/jats:p>","DOI":"10.1177\/08971900231182772","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T17:53:00Z","timestamp":1686333180000},"page":"780-785","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["A Case Series on Serotonin Syndrome from Concomitant use of linezolid With Methadone, Buprenorphine, and\/or Dextroamphetamine"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6601-0365","authenticated-orcid":false,"given":"Joanne","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA."},{"name":"Department of Pharmacy, UW Medicine, Valley Medical Center, Renton, WA, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7337-1046","authenticated-orcid":false,"given":"Heba","family":"Edrees","sequence":"additional","affiliation":[{"name":"Division of General and Internal Medicine, Brigham and Women\u2019s Hospital, Boston, MA, USA"},{"name":"Harvard TH Chan School of Public Health, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UW Medicine, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"bibr1-08971900231182772","volume-title":"Zyvox Package Insert","year":"2021"},{"key":"bibr2-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg109"},{"key":"bibr3-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041867"},{"issue":"2","key":"bibr4-08971900231182772","first-page":"214","volume":"29","author":"Sutton J","year":"2016","journal-title":"SAVE Proc"},{"key":"bibr5-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R386"},{"key":"bibr6-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2022.08.030"},{"key":"bibr7-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2020.1839662"},{"key":"bibr8-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2020.12.014"},{"key":"bibr9-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.5144"},{"issue":"1","key":"bibr10-08971900231182772","first-page":"E27","volume":"18","author":"Koury KM","year":"2015","journal-title":"Pain Physician"},{"key":"bibr11-08971900231182772","volume-title":"Drug Interaction between Linezolid and Serotonergic Psychiatric Med"},{"key":"bibr12-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.2.269"},{"key":"bibr13-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1086\/503839"},{"key":"bibr14-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-02990-1"},{"key":"bibr15-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2006.9.1257"},{"key":"bibr16-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2008.01.003"},{"key":"bibr17-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2008.01.039"},{"key":"bibr18-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr467"},{"key":"bibr19-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00921-13"},{"key":"bibr20-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1086\/504809"},{"key":"bibr21-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy916"},{"key":"bibr22-08971900231182772","volume-title":"The CBHSQ Report","author":"Alderks CE","year":"2013"},{"key":"bibr23-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-016-2638-2"},{"key":"bibr24-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac331"},{"key":"bibr25-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106843"},{"key":"bibr26-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R604"},{"key":"bibr27-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2008.08.009"},{"key":"bibr28-08971900231182772","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.11.1000"},{"key":"bibr29-08971900231182772","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2011.596974"},{"key":"bibr30-08971900231182772","volume-title":"Dextroamphetamine-Amphetamine. [Updated 2022 May 29]. In: StatPearls [Internet]","author":"Sharbaf Shoar N","year":"2022"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900231182772","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900231182772","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900231182772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:38:10Z","timestamp":1777509490000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900231182772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1177\/08971900231182772"],"URL":"https:\/\/doi.org\/10.1177\/08971900231182772","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}